Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

All the figurative FDA trains are running on time, according to the agency’s leader Marty Makary, M.D. | “I'm proud to report ...

PwC analysts have warned the speedy evolution of the Chinese biotech sector is creating “heightened risks related to IP ...

A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in ...

A pair of professional organizations in the U.K. is calling for the biopharma industry and national government to take action ...

Philips is rolling out what it describes as a next-generation point-of-care ultrasound system, designed specifically for ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...

The FDA is introducing a new priority voucher program designed to shorten the drug review process from 10 to 12 months down to one or two months, according to the agency. | The FDA is introducing a ...

Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around ...

Dexcom is working to replace some of the receivers that link with its continuous glucose monitoring systems due to a ...

KalVista Pharmaceuticals has become the latest biotech to face delays to the FDA’s decision-making, as the agency apparently ...

When Eli Lilly snapped up Scorpion Therapeutics' PI3Kα program earlier this year, the deal allowed Scorpion to spin out a new ...